JP2017160178A5 - - Google Patents

Download PDF

Info

Publication number
JP2017160178A5
JP2017160178A5 JP2016108649A JP2016108649A JP2017160178A5 JP 2017160178 A5 JP2017160178 A5 JP 2017160178A5 JP 2016108649 A JP2016108649 A JP 2016108649A JP 2016108649 A JP2016108649 A JP 2016108649A JP 2017160178 A5 JP2017160178 A5 JP 2017160178A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
weeks
antagonist
antibody
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016108649A
Other languages
English (en)
Japanese (ja)
Other versions
JP6654967B2 (ja
JP2017160178A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2017160178A publication Critical patent/JP2017160178A/ja
Publication of JP2017160178A5 publication Critical patent/JP2017160178A5/ja
Application granted granted Critical
Publication of JP6654967B2 publication Critical patent/JP6654967B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016108649A 2015-04-14 2016-05-31 Il−31アンタゴニストを有効成分として含有する、アトピー性皮膚炎の予防用及び/又は治療用医薬組成物 Active JP6654967B2 (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2015082699 2015-04-14
JP2015082699 2015-04-14
JP2016041641 2016-03-04
JP2016041641 2016-03-04

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2016522817A Division JP5954916B1 (ja) 2015-04-14 2016-04-13 Il−31アンタゴニストを有効成分として含有する、アトピー性皮膚炎の予防用及び/又は治療用医薬組成物

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020015220A Division JP6887212B2 (ja) 2015-04-14 2020-01-31 Il−31アンタゴニストを有効成分として含有する、アトピー性皮膚炎の予防用及び/又は治療用医薬組成物

Publications (3)

Publication Number Publication Date
JP2017160178A JP2017160178A (ja) 2017-09-14
JP2017160178A5 true JP2017160178A5 (enExample) 2019-05-23
JP6654967B2 JP6654967B2 (ja) 2020-02-26

Family

ID=57126544

Family Applications (7)

Application Number Title Priority Date Filing Date
JP2016522817A Active JP5954916B1 (ja) 2015-04-14 2016-04-13 Il−31アンタゴニストを有効成分として含有する、アトピー性皮膚炎の予防用及び/又は治療用医薬組成物
JP2016108649A Active JP6654967B2 (ja) 2015-04-14 2016-05-31 Il−31アンタゴニストを有効成分として含有する、アトピー性皮膚炎の予防用及び/又は治療用医薬組成物
JP2020015220A Active JP6887212B2 (ja) 2015-04-14 2020-01-31 Il−31アンタゴニストを有効成分として含有する、アトピー性皮膚炎の予防用及び/又は治療用医薬組成物
JP2021066854A Withdrawn JP2021105051A (ja) 2015-04-14 2021-04-12 Il−31アンタゴニストを有効成分として含有する、アトピー性皮膚炎の予防用及び/又は治療用医薬組成物
JP2021149027A Pending JP2021193124A (ja) 2015-04-14 2021-09-14 Il−31アンタゴニストを有効成分として含有する、アトピー性皮膚炎の予防用及び/又は治療用医薬組成物
JP2023123359A Pending JP2023134842A (ja) 2015-04-14 2023-07-28 Il-31アンタゴニストを有効成分として含有する、アトピー性皮膚炎の予防用及び/又は治療用医薬組成物
JP2025086586A Pending JP2025122131A (ja) 2015-04-14 2025-05-23 Il-31アンタゴニストを有効成分として含有する、アトピー性皮膚炎の予防用及び/又は治療用医薬組成物

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2016522817A Active JP5954916B1 (ja) 2015-04-14 2016-04-13 Il−31アンタゴニストを有効成分として含有する、アトピー性皮膚炎の予防用及び/又は治療用医薬組成物

Family Applications After (5)

Application Number Title Priority Date Filing Date
JP2020015220A Active JP6887212B2 (ja) 2015-04-14 2020-01-31 Il−31アンタゴニストを有効成分として含有する、アトピー性皮膚炎の予防用及び/又は治療用医薬組成物
JP2021066854A Withdrawn JP2021105051A (ja) 2015-04-14 2021-04-12 Il−31アンタゴニストを有効成分として含有する、アトピー性皮膚炎の予防用及び/又は治療用医薬組成物
JP2021149027A Pending JP2021193124A (ja) 2015-04-14 2021-09-14 Il−31アンタゴニストを有効成分として含有する、アトピー性皮膚炎の予防用及び/又は治療用医薬組成物
JP2023123359A Pending JP2023134842A (ja) 2015-04-14 2023-07-28 Il-31アンタゴニストを有効成分として含有する、アトピー性皮膚炎の予防用及び/又は治療用医薬組成物
JP2025086586A Pending JP2025122131A (ja) 2015-04-14 2025-05-23 Il-31アンタゴニストを有効成分として含有する、アトピー性皮膚炎の予防用及び/又は治療用医薬組成物

Country Status (25)

Country Link
US (3) US10544227B2 (enExample)
EP (2) EP3284480B1 (enExample)
JP (7) JP5954916B1 (enExample)
KR (4) KR102886159B1 (enExample)
CN (2) CN107614016B (enExample)
AU (2) AU2016248786B2 (enExample)
BR (1) BR112017022101A2 (enExample)
CA (1) CA2980992C (enExample)
DK (1) DK3284480T3 (enExample)
ES (1) ES3036076T3 (enExample)
FI (2) FI3284480T3 (enExample)
FR (1) FR25C1042I1 (enExample)
HR (1) HRP20250972T1 (enExample)
HU (2) HUE072989T2 (enExample)
LT (2) LT3284480T (enExample)
MA (1) MA43918A (enExample)
MX (2) MX390570B (enExample)
NL (1) NL301347I2 (enExample)
NO (1) NO2025047I1 (enExample)
PL (1) PL3284480T3 (enExample)
PT (1) PT3284480T (enExample)
RU (1) RU2749512C2 (enExample)
SI (1) SI3284480T1 (enExample)
TW (4) TWI738648B (enExample)
WO (1) WO2016167263A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5954916B1 (ja) 2015-04-14 2016-07-20 中外製薬株式会社 Il−31アンタゴニストを有効成分として含有する、アトピー性皮膚炎の予防用及び/又は治療用医薬組成物
WO2017126488A1 (ja) * 2016-01-18 2017-07-27 持田製薬株式会社 乾癬治療用組成物および治療方法
US10093731B2 (en) 2017-02-24 2018-10-09 Kindred Biosciences, Inc. Anti-IL31 antibodies for veterinary use
JP7777921B2 (ja) * 2018-02-09 2025-12-01 ガルデルマ ホールディング エスエー 中等度から重度の掻破痕を有するアトピー性皮膚炎の治療におけるネモリズマブ
BR112020021739A2 (pt) * 2018-04-25 2021-01-26 Kiniksa Phamaceuticals, Ltd. tratamento de doenças ou distúrbios de pele pela liberação do anticorpo anti-osmrbeta
CN112512480B (zh) 2018-05-21 2024-10-01 中外制药株式会社 被封入玻璃容器的冷冻干燥制剂
CN113544153B (zh) * 2019-01-03 2024-12-10 因外泰克斯公司 用于增加治疗剂在犬中的半衰期的组合物及使用方法
BR112022002771A2 (pt) * 2019-08-29 2022-08-09 Kindred Biosciences Inc Anticorpos anti-il31 para uso veterinário
CN110563844A (zh) * 2019-09-04 2019-12-13 华中农业大学 一种抗犬白介素31受体的多克隆抗体及其应用
MX2022005654A (es) 2019-11-20 2022-06-22 Chugai Pharmaceutical Co Ltd Preparacion que contiene anticuerpo.
WO2021151059A1 (en) * 2020-01-24 2021-07-29 Arizona Board Of Regents On Behalf Of The University Of Arizona Compounds and methods for treating or reducing pruritus
WO2022113316A1 (ja) * 2020-11-30 2022-06-02 マルホ株式会社 線維化の進行抑制剤
US20220411518A1 (en) * 2021-04-07 2022-12-29 Galderma Holding S.A. Treatments for prurigo nodularis
CN115181183B (zh) * 2022-06-23 2023-11-03 恺佧生物科技(上海)有限公司 一种il-31ra抗体以及其构建方法

Family Cites Families (88)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH575014A5 (enExample) 1973-05-25 1976-04-30 Alusuisse
JPS5328498Y2 (enExample) 1973-08-17 1978-07-18
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
BR9204244A (pt) 1992-10-26 1994-05-03 Cofap Ferro fundido cinzento
CZ140195A3 (en) 1992-12-01 1996-06-12 Protein Desing Labs Humanized antibodies reacting with l-selectin
FR2707189B1 (fr) 1993-07-09 1995-10-13 Gradient Ass Procédé de traitement de résidus de combustion et installation de mise en Óoeuvre dudit procédé.
FR2729855A1 (fr) 1995-01-26 1996-08-02 Oreal Utilisation d'un antagoniste de cgrp dans une composition cosmetique, pharmaceutique ou dermatologique et composition obtenue
US5876950A (en) 1995-01-26 1999-03-02 Bristol-Myers Squibb Company Monoclonal antibodies specific for different epitopes of human GP39 and methods for their use in diagnosis and therapy
ES2233974T3 (es) 1995-09-11 2005-06-16 Kyowa Hakko Kogyo Co., Ltd. Anticuerpo contra la cadena alfa del receptor de la interleucina 5 humana.
EP0852951A1 (de) 1996-11-19 1998-07-15 Roche Diagnostics GmbH Stabile lyophilisierte pharmazeutische Zubereitungen von mono- oder polyklonalen Antikörpern
CN1241944A (zh) 1996-12-05 2000-01-19 乔治敦大学 具有抗病毒活性的鼠尾草种类的提取物
JPH11101542A (ja) 1997-09-29 1999-04-13 Sanyo Electric Co Ltd 冷蔵庫
DK1071700T3 (da) 1998-04-20 2010-06-07 Glycart Biotechnology Ag Glykosylerings-modifikation af antistoffer til forbedring af antistofafhængig cellulær cytotoksicitet
JP3979008B2 (ja) 1998-04-30 2007-09-19 タノックス インコーポレイテッド G−csfレセプターアゴニスト抗体及びそのスクリーニング方法
FR2780062B1 (fr) 1998-06-17 2000-07-28 Rhone Poulenc Rorer Sa Anticorps monoclonaux diriges contre la proteine g3bp, et leurs utilisations
WO1999067290A1 (fr) 1998-06-24 1999-12-29 Chugai Research Institute For Molecular Medicine, Inc. Nouvelles proteines receptrices d'hemopoïetine
AU776910B2 (en) 1998-12-08 2004-09-23 Merck Patent Gesellschaft Mit Beschrankter Haftung Modifying protein immunogenicity
CA2704600C (en) 1999-04-09 2016-10-25 Kyowa Kirin Co., Ltd. A method for producing antibodies with increased adcc activity
EP2325316B8 (en) 1999-06-02 2017-04-19 Chugai Seiyaku Kabushiki Kaisha Novel hemopoietin receptor protein, NR10
AU7445900A (en) 1999-09-27 2001-04-30 Chugai Seiyaku Kabushiki Kaisha Novel hemopoietin receptor protein, nr12
CN1326880A (zh) 2000-06-06 2001-12-19 周伟中 双层站台火车站
CA2412239C (en) 2000-06-26 2013-05-28 Zymogenetics, Inc. Cytokine receptor zcytor17
US20030096339A1 (en) 2000-06-26 2003-05-22 Sprecher Cindy A. Cytokine receptor zcytor17
EP1332209B1 (en) 2000-09-08 2009-11-11 Universität Zürich Collections of repeat proteins comprising repeat modules
EP2141243A3 (en) 2000-10-16 2010-01-27 Brystol-Myers Squibb Company Protein scaffolds for antibody mimics and other binding proteins
WO2002077230A1 (fr) 2001-03-26 2002-10-03 Chugai Seiyaku Kabushiki Kaisha Variants d'epissage nr10
US20040234524A1 (en) 2001-04-05 2004-11-25 Toshimitsu Uede Anti-osteopontin antibody and use thereof
US20030157561A1 (en) 2001-11-19 2003-08-21 Kolkman Joost A. Combinatorial libraries of monomer domains
DK1961811T3 (da) 2002-01-18 2010-11-08 Zymogenetics Inc Cytokinligand til behandling af asthma og luftvejs-hyper-responsivitet
EP2840089A1 (en) 2002-01-18 2015-02-25 ZymoGenetics, Inc. Cytokine receptor zcytor17 multimers
SI1485477T1 (sl) 2002-02-25 2009-10-31 Genentech Inc Novi citokinski receptor GLM-R tipa 1
US7579000B2 (en) 2002-05-01 2009-08-25 Bayer Schering Pharma Ag Tissue factor targeted antibodies as anticoagulants
HK1080372A1 (zh) 2002-05-01 2006-04-28 Schering Aktiengesellschaft 作为抗凝剂的新型组织因子目标抗体
TW200407335A (en) 2002-07-22 2004-05-16 Chugai Pharmaceutical Co Ltd Non-neutralizing antibody to inhibit the inactivation of activated protein C
KR100499989B1 (ko) 2002-12-27 2005-07-07 네오바이오다임 주식회사 아사이알로 α1-산 당단백질에 대한 단일클론 항체, 이 항체를 포함하는 아사이알로 α1-산 당단백질에 대한 단일클론 항체, 이 항체를 포함하는 면역크로마토그래피 스트립 및 이 스트립를 이용한 아사이알로 α1-산 당단백질 측정방법
US20040223970A1 (en) 2003-02-28 2004-11-11 Daniel Afar Antibodies against SLC15A2 and uses thereof
NZ542134A (en) 2003-03-04 2009-06-26 Alexion Pharma Inc Method of treating autoimmune disease by inducing antigen presentation by tolerance inducing antigen presenting cells
JP2007525438A (ja) 2003-03-24 2007-09-06 ザイモジェネティクス, インコーポレイテッド 抗il−22ra抗体および結合パートナー、ならびに炎症における使用法
WO2005079566A2 (en) 2004-02-12 2005-09-01 Lexicon Genetics Incorporated Gene disruptions, compositions and methods relating thereto
CA2572133A1 (en) 2004-06-25 2006-01-12 Medimmune, Inc. Increasing the production of recombinant antibodies in mammalian cells by site-directed mutagenesis
KR100624013B1 (ko) 2004-06-25 2006-09-19 주식회사 녹십자홀딩스 동결건조된 알부민 비함유 재조합 사람 혈액응고 제 8인자 제제
EP1671642A1 (en) 2004-12-15 2006-06-21 Universite D'angers Compositions comprising (ant)agonists of oncostatin M (OSM), IL-31 and IFN-gamma for modulating keratinocyte migration and functions via a receptor containing OSMRbeta as a subunit, and applications thereof.
PT1831258E (pt) 2004-12-28 2016-01-07 Univ Genova Anticorpos monoclonais contra nkg2a
JP2008528039A (ja) 2005-01-28 2008-07-31 ザイモジェネティクス,インコーポレイティド Il−31の均質調製物
WO2006088955A2 (en) 2005-02-14 2006-08-24 Zymogenetics, Inc. Methods of treating diseases which are mediated by cutaneous lymphocyte antigen positive cells
EP1858924A1 (en) 2005-02-14 2007-11-28 ZymoGenetics, Inc. Methods of treating skin disorders using an il-31ra antagonist
UY29504A1 (es) 2005-04-29 2006-10-31 Rinat Neuroscience Corp Anticuerpos dirigidos contra el péptido amiloide beta y métodos que utilizan los mismos.
US8003108B2 (en) 2005-05-03 2011-08-23 Amgen Inc. Sclerostin epitopes
RU2444528C2 (ru) 2005-05-06 2012-03-10 Займоджинетикс, Инк. Моноклональные антитела против il-31 и способы применения
KR101443050B1 (ko) 2005-05-06 2014-09-22 지모제넥틱스, 인코포레이티드 Il-31 단클론성 항체 및 사용법
EP2749571A3 (en) 2006-01-10 2014-08-13 ZymoGenetics, Inc. Methods of treating pain and inflammation in neuronal tissue using IL-31RA and OSMRb antagonists
SG10201400426XA (en) 2006-01-12 2014-07-30 Alexion Pharma Inc Antibodies to ox-2/cd200 and uses thereof
RU2429244C2 (ru) 2006-03-23 2011-09-20 Байоарктик Ньюросайенс Аб Улучшенные селективные в отношении протофибрилл антитела и их применение
ES2429407T3 (es) 2006-06-08 2013-11-14 Chugai Seiyaku Kabushiki Kaisha Agente preventivo o remedio para enfermedades inflamatorias
ES2415655T3 (es) 2006-06-15 2013-07-26 The Board Of Trustees Of The University Of Arkansas Anticuerpos monoclonales que reconocen selectivamente Metanfetamina y compuestos similares a Metanfetamina
ES2548714T3 (es) 2006-09-01 2015-10-20 Zymogenetics, Inc. Anticuerpos monoclonales IL-31 y procedimientos de uso
BRPI0720280A2 (pt) 2006-12-11 2014-01-28 Wyeth Corp Métodos e composições para tratar e monitorar tratamento de desordens associadas à il-13
CN101600456A (zh) * 2006-12-11 2009-12-09 惠氏公司 治疗il-13相关疾病和监测il-13相关疾病治疗的方法和组合物
US7919594B2 (en) 2007-02-14 2011-04-05 Vaccinex, Inc. Human anti-CD100 antibodies
ES2708988T3 (es) 2007-02-23 2019-04-12 Merck Sharp & Dohme Anticuerpos anti-IL-23p19 obtenidos por ingeniería genética
JPWO2008114733A1 (ja) 2007-03-16 2010-07-01 協和発酵キリン株式会社 抗Claudin−4抗体
GB0708002D0 (en) 2007-04-25 2007-06-06 Univ Sheffield Antibodies
EP2167127A1 (en) 2007-07-10 2010-03-31 F. Hoffmann-Roche AG Novel formulation
ES2595638T3 (es) * 2007-09-26 2017-01-02 Chugai Seiyaku Kabushiki Kaisha Método para modificar el punto isoeléctrico de un anticuerpo mediante la sustitución de aminoácidos en una CDR
KR101680906B1 (ko) 2007-09-26 2016-11-30 추가이 세이야쿠 가부시키가이샤 항체 정상영역 개변체
MX2010003329A (es) 2007-09-26 2010-04-27 Chugai Pharmaceutical Co Ltd Anticuerpo anti-receptor de il-6.
CA2708065C (en) * 2007-12-05 2015-02-24 Chugai Seiyaku Kabushiki Kaisha Therapeutic agent for pruritus
TW201634479A (zh) 2007-12-05 2016-10-01 中外製藥股份有限公司 抗nr10抗體及其應用
ME03057B (me) 2007-12-07 2019-01-20 Zymogenetics Inc Molekuli humanizovanih antitela specifični za il-31
KR20160062207A (ko) * 2008-12-05 2016-06-01 추가이 세이야쿠 가부시키가이샤 항nr10 항체 및 그의 이용
JP2010210772A (ja) 2009-03-13 2010-09-24 Dainippon Screen Mfg Co Ltd 液晶表示装置の製造方法
EP3679942A1 (en) 2009-06-17 2020-07-15 BioMarin Pharmaceutical Inc. Formulations for lysosomal enzymes
WO2013012022A1 (ja) 2011-07-19 2013-01-24 中外製薬株式会社 アルギニンアミドまたはその類似化合物を含む安定なタンパク質含有製剤
US8790651B2 (en) 2011-07-21 2014-07-29 Zoetis Llc Interleukin-31 monoclonal antibody
PT3889181T (pt) 2012-09-07 2024-05-29 Regeneron Pharma Um anticorpo antagonista de il-4r para utilização no tratamento da dermatite atópica por administração
WO2014145159A2 (en) 2013-03-15 2014-09-18 Permeon Biologics, Inc. Charge-engineered antibodies or compositions of penetration-enhanced targeting proteins and methods of use
US9198898B2 (en) * 2013-06-24 2015-12-01 Tigercat Pharma, Inc. Use of NK-1 receptor antagonists in pruritus
TW201537175A (zh) 2013-06-28 2015-10-01 Chugai Pharmaceutical Co Ltd 預測罹患具皮膚搔癢之疾病的患者對il-31拮抗劑之治療的反應之方法
JP5954916B1 (ja) 2015-04-14 2016-07-20 中外製薬株式会社 Il−31アンタゴニストを有効成分として含有する、アトピー性皮膚炎の予防用及び/又は治療用医薬組成物
GB201703063D0 (en) 2017-02-24 2017-04-12 Arecor Ltd Stabilized antibody protein solutions
WO2018156367A1 (en) 2017-02-24 2018-08-30 Kindred Biosciences, Inc. Anti-il31 antibodies for veterinary use
US10554227B2 (en) * 2017-03-10 2020-02-04 Western Digital Technologies, Inc. Decoding optimization for channel mismatch
MX2019012255A (es) 2017-04-11 2019-12-05 Kiniksa Pharmaceuticals Ltd Formulacion estable de anticuerpo contra el receptor de oncostatina m (osmr).
CN112512480B (zh) 2018-05-21 2024-10-01 中外制药株式会社 被封入玻璃容器的冷冻干燥制剂
MX2022005654A (es) 2019-11-20 2022-06-22 Chugai Pharmaceutical Co Ltd Preparacion que contiene anticuerpo.
US20230391878A1 (en) 2020-09-01 2023-12-07 Chugai Seiyaku Kabushiki Kaisha Pharmaceutical composition for prevention and/or treatment of dialysis pruritus containing il-31 antagonist as active ingredient
WO2022113316A1 (ja) 2020-11-30 2022-06-02 マルホ株式会社 線維化の進行抑制剤
WO2023120561A1 (ja) 2021-12-22 2023-06-29 中外製薬株式会社 生物活性が低下した抗体バリアント

Similar Documents

Publication Publication Date Title
JP2017160178A5 (enExample)
RU2017138551A (ru) Фармацевтическая композиция для профилактики и/или лечения атопического дерматита, включающая антагонист ил-31 в качестве активного ингредиента
JP2017160208A5 (enExample)
JP2018184417A5 (enExample)
JP2015529225A5 (enExample)
JP2015525798A5 (enExample)
JP2020518599A5 (enExample)
JP2016528247A5 (enExample)
IL316404A (en) A safe and effective method for treating psoriasis with a specific anti-IL23 antibody
RU2017134443A (ru) Способ лечения с применением традипитанта
JP2017503820A5 (enExample)
JP2006522830A5 (enExample)
JP2014114288A5 (enExample)
CY1119886T1 (el) Μεθοδος βιομηχανικης κατασκευης μιας φαρμακευτικης συνθεσης στην μορφη δισκιων παρατεταμενης απελευθερωσης που περιεχουν πιρφενιδονη και χρηση αυτων στην υποστροφη χρονιας νεφρικης ανεπαρκειας, καψικης συσπασης μαστου και ηπατικης ινωσης σε ανθρωπους
JP2015007098A5 (enExample)
JP2016530280A5 (enExample)
JP2022160685A5 (enExample)
JP2016185995A5 (enExample)
JP2018515493A5 (enExample)
JP2020502219A5 (enExample)
JP2018530578A5 (enExample)
JP2020535149A5 (enExample)
JP2019532970A5 (enExample)
JP2015172060A5 (enExample)
JP2022041802A5 (enExample)